Core Insights - Bleximenib, an investigational selective menin inhibitor, demonstrates potential as a combination therapy for relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed, intensive chemotherapy-ineligible AML [1][2] - The Phase 1b study shows promising efficacy and safety data, with an overall response rate (ORR) of 82% for relapsed or refractory AML and 90% for newly diagnosed patients [2][3] - The safety profile indicates a low rate of differentiation syndrome and no significant cardiac safety signals, supporting further investigation in Phase 2 and 3 studies [1][2][3] Company Overview - Johnson & Johnson is committed to addressing unmet medical needs in hematologic malignancies, focusing on innovative treatment options for AML [2][8] - The company is exploring the potential of bleximenib both as a monotherapy and in combination with standard care regimens in ongoing clinical trials [6][8] Industry Context - Acute myeloid leukemia is the most common type of acute leukemia in adults, characterized by low survival rates and poor patient outcomes, particularly in those with KMT2A gene rearrangements and NPM1 mutations [2][7] - The five-year survival rate for AML remains the lowest among leukemias, highlighting the urgent need for effective treatment options [7]

Omeros Corporation OMER on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML).AML is the most fatal form of leukemia. It accounts for approximately 80% of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow.Omeros’ OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the can ...